HIMS
holds · 5.5% allocation
Conviction over time
Sentiment weighted by conviction, oldest to newest — above the line is bullish
Price targets
How each level moved over time. The last value is his current one.
Trades
What he actually did, newest first
-
07 Jul 26
WOLF reached his buying target so he added a bit more
-
01 Jul 26
no trades executed this month; allocation shifts are purely from price action
-
31 May 26
Bought some Wolfspeed in the beginning of the month.
-
31 May 26
Bought some Fluence in the beginning of the month.
-
31 May 26
Sold his TMDX shares.
-
31 May 26
Sold ASML shares (+13% in 3 months) to fund a SK Hynix purchase.
-
31 May 26
Bought SK Hynix using proceeds from selling ASML; wishes he had bought more three months ago (+114% since).
-
26 May 26
09/03 call
-
26 May 26
10/03 call
-
26 May 26
11/03 call
-
26 May 26
11/03 call
-
26 May 26
31/03 call
-
26 May 26
31/03 call
-
26 May 26
31/03 call
-
26 May 26
20/04 call
-
26 May 26
27/04, closed the position
-
26 May 26
05/05 call
-
26 May 26
07/05 call
-
10 May 26
Recently added to the position, now up almost 30%
-
10 May 26
Does not plan to add much more despite being underwater
-
08 May 26
Buy at 487 on 09/03
-
08 May 26
Buy at 20 on 10/03
-
08 May 26
Buy at 88.66 on 11/03
-
08 May 26
Buy at 6.52 on 11/03
-
08 May 26
Buy at 4.9 on 31/03
-
08 May 26
Buy at 16.7 on 31/03
-
08 May 26
Buy at 18.7 on 31/03
-
08 May 26
Buy at 230 on 20/04
-
08 May 26
Sold at 8 on 27/04
-
08 May 26
Buy at 36 on 05/05
-
08 May 26
Buy at 16.67 on 07/05
-
01 May 26
sold this month to raise cash
-
01 May 26
sold this month to raise cash
-
01 May 26
sold this month to raise cash
-
01 May 26
only buy made this month
-
01 May 26
wants to add more to bring FTC up from 4.5% allocation, waiting for a better moment to buy
-
06 Apr 26
bought additional shares last week
-
05 Apr 26
initiated new position
-
05 Apr 26
initiated new position
-
05 Apr 26
initiated new position, up 15% since entry
-
05 Apr 26
initiated new position in SK Hynix
-
05 Apr 26
bought extra shares, continuing to DCA
-
05 Apr 26
plans to add 1 new position as part of concentrating the portfolio
-
05 Apr 26
plans to sell 5 to 6 positions to bring total holdings from 16 down to 11
-
01 Apr 26
recently bought some extra HIMS
-
31 Mar 26
one of 3 buys made yesterday
-
31 Mar 26
one of 3 buys made yesterday
-
31 Mar 26
one of 3 buys made yesterday
-
29 Mar 26
Tentative, undecided candidate for adding to ('don't know yet, probably')
-
29 Mar 26
Tentative, undecided candidate for adding to ('don't know yet, probably')
-
07 Mar 26
Added shares in the last couple of weeks
-
27 Feb 26
Made zero trades in February — no panic selling, no chasing trends, no attempt to time the bottom
-
19 Feb 26
Confident to add given recent acquisitions and valuation disconnect
-
02 Feb 26
Did not buy or sell anything during January, portfolio composition unchanged.
Reasoning trail
Every post mentioning HIMS, newest first — the thesis as it was built and revised
-
23 Jul 26
Welcomes the bullish HIMS news as overdue good news for the stock.
-
21 Jul 26
Names HIMS as his GLP-1 pick.
-
16 Jul 26
Asked which tickers among previously discussed targets have the least chance of hitting them; names HIMS, GOOGL and MRVL as least likely.
-
15 Jul 26
Names his top 5 preferred stocks to buy if all his buy targets are hit and the market recovers: PL, OUST, MRVL, FLNC, HIMS.
-
07 Jul 26
After being offline during a move, says he's calm in this market; WOLF hit his buying target so he added a bit more at $34.3, and restates his full watchlist of buy/add targets across many tickers.
-
01 Jul 26
Monthly portfolio update: MTD -3.7%, YTD +94.1%, no trades this month, allocation shifts purely from price action across 14 positions including Planet Labs, Ouster, Rocket Lab, Marvell, SK Hynix, ASM International, Palantir, Fluence, Hims, Google, Iren, Wolfspeed, Amprius and Filtronic.
-
27 Jun 26
Publishes his personal add-target levels across his portfolio, based on allocation sizing and how undervalued each stock is, and says he'll try to stay patient.
-
31 May 26
Monthly portfolio update: MTD +40.4%, YTD +97.8%. Bought WOLF and FLNC early in the month, sold TMDX, and sold ASML to fund a SK Hynix purchase (wishes he'd bought more three months ago). Cash allocation ~11.6% and building slightly via savings, not sales. Reviews all 14 core holdings with performance, allocation and outlook: PL (target $60 by year end, earnings 4/6), RKLB (surged on strong earnings), OUST (long-term hold, no longer buy territory), PLTR (favorite AI software play, #1 holding), SK Hynix (regrets not buying more), AMPX (bullish long-term on batteries/drones), IREN (highest-cost holding, datacenter thesis), MRVL (photonics center, healthy balance sheet), ASM.AS (longest-held, safe-haven, €1,000 target where he may trim), Filtronic (SpaceX GaN amp supplier), WOLF (bullish long-term, BoA target >$80), FLNC (Hyperscaler contracts, next quarters crucial), GOOGL (could become most valuable company), HIMS (small 3.7% allocation, may add).
-
26 May 26
Recaps a public call track record over ~2.5 months on a hypothetical $1K-per-call basis: buys in SK Hynix, OUST, MRVL, POET (twice), HIMS, Filtronic, WOLF, FLNC, and a sale of POET at 8; reports total invested 10K growing to 18.77K, an 87.70% return.
-
15 May 26
Argues against the narrative that concentration is required to beat the market, citing his own track record of holding 12-17 stocks (avg 15) while beating the S&P 500 every year since 2023, with a portfolio breakdown showing Planet Labs, Rocket Lab, Palantir, Ouster and others as top holdings.
-
11 May 26
Replies about his space telecommunications document, noting he owns HIMS but not ASTS, so he'll start with the HIMS earnings call.
-
11 May 26
Flags that both HIMS and ASTS are down about 11% after hours following earnings, and that he plans to listen to both calls the next day.
-
10 May 26
Clarifies HIMS is his only underwater position; he recently added to WOLF and is up ~30% on it; plans to keep holding HIMS long term, believing the GLP-1 opportunity is underestimated, though it's his largest cost-basis position so he won't add much more.
-
10 May 26
Replying about $HIMS, says he is still in the red overall on the position but still believes in the company.
-
10 May 26
Full monthly portfolio update: 15% cash plus 14 named positions with allocation percentages and average cost basis / gain per position, from $PL as largest (16%) down to $HIMS smallest (4.7%, currently at a loss).
-
08 May 26
Recaps a hypothetical $1K-per-decision portfolio of his last 2 months of calls, showing a 53.85% total return across SK Hynix, OUST, MRVL, POET (bought twice, sold), HIMS, Filtronic, WOLF, and FLNC.
-
01 May 26
Publishes management-quality scores for his full current holding list under his rating framework: GOOGL 97, FTC 96, SK Hynix 93, ASM.AS 92, OUST 90, PL 89, MRVL 88, PLTR 87, TMDX 87, HIMS 85, RKLB 79, AMPX 75, FLNC 73, IREN 35 — generally praising execution and capital discipline, with dilution and guidance misses as the main detractors, and IREN scored lowest for promotional narrative pivots and heavy dilution.
-
01 May 26
Monthly portfolio update: best month ever at +48.49% return. Raised cash by selling POET, HOOD and CROWD; only buy was FTC (Filtronic). Wants to add to FTC (currently 4.5% allocation) but is waiting for a better entry. 45% of holdings report earnings next week, especially TMDX and FLNC, his worst performers now under 3% allocation each — earnings will decide whether he trims or adds. Plans to move toward a more concentrated ~12-stock portfolio and expects more trading this month.
-
21 Apr 26
Highlights three recent buys that have surged in the last three weeks — HIMS +62.5%, OUST +73.8%, POET +114% — and says it's only the beginning.
-
16 Apr 26
Reports strong gains on HIMS, OUST, and POET bought two weeks earlier.
-
07 Apr 26
Notes the HIMS-Novo Nordisk partnership is fully restored after collapsing in June 2025 when HIMS traded at $61.
-
07 Apr 26
Remains a $HIMS bull but is troubled by the CFO selling 75% of his shares; argues the timing (now at ~$20 rather than months ago at ~$50) undercuts the 'anticipating a bad quarter' explanation and reflects poorly on the company.
-
06 Apr 26
Says he bought extra HIMS shares last week.
-
05 Apr 26
Monthly portfolio update: up 6.9% in March, led by PL, PLTR, RKLB and AMPX; initiated four new positions (OUST, POET, MRVL, SK Hynix), added to HIMS; TMDX, HOOD, FLNC and IREN declined; plans to cut cash from 20% to 10% and consolidate from 16 to 11 holdings.
-
02 Apr 26
Agrees HIMS should eventually be re-rated by the market, but thinks the broader peptides boom still has years to play out.
-
02 Apr 26
Agrees HIMS and OUST have massive upside but says the rise is conditional on the current war ending.
-
01 Apr 26
Bullish, high-conviction thesis that HIMS is undervalued and well positioned to capture the growing GLP-1/peptide wave via platform expansion and acquisitions; recently added to the position.
-
31 Mar 26
Made three buys the prior day — HIMS at $18.70, OUST at $16.70, and POET at $4.90 — and reiterates HIMS looks very undervalued right now.
-
29 Mar 26
Thanks a follower for sharing, says he'll share his own decision once made, and congratulates them on HIMS.
-
29 Mar 26
Says he doesn't yet know what he'll add to, but is probably looking at HIMS and OUST.
-
18 Mar 26
Discloses he also holds $HIMS in his portfolio.
-
15 Mar 26
Jokingly reacts with the HIMS ticker to a post about a losing position rebounding slightly.
-
12 Mar 26
Highlights that the last 6 times $HIMS broke above its 21-day SMA it triggered a massive rally (only 1 false breakout), and asks if another rally is coming. Attached chart shows the pattern.
-
11 Mar 26
Reports his biggest winners of the day were IREN, OUST, and HIMS, all up more than 10%, implying he holds all three.
-
11 Mar 26
Asks moninvestor whether they are buying HIMS again, noting he thought they had sold it.
-
11 Mar 26
Apologizes for a labeling mistake, explaining he reused/adapted his HIMS visual template for this other post.
-
09 Mar 26
Long bullish thesis on HIMS: argues GLP-1 drugs are broader than an obesity treatment, with LLY and NVO currently controlling supply via patents. As patents expire and prescriptions widen, HIMS is positioned as the customer-facing platform with a de facto monopoly, especially given its dispute/settlement with Novo. Author reaffirms his HIMS business case despite the stock being down 25% since his research and his December price targets now looking out of proportion.
-
07 Mar 26
Confirms he is invested in HIMS in response to a question about the potential short squeeze.
-
07 Mar 26
Names HIMS as a stock he thinks could easily 10x over the next decade.
-
07 Mar 26
Bullish on HIMS after Novo dropped its lawsuit, allowing HIMS to sell Novo GLP-1 products again; says he added shares recently and views HIMS as well positioned for the next pharma revolution.
-
02 Mar 26
Responding to a question about Novo Nordisk, says the pill launch is promising but they need an easy distribution channel to the customer (suggests HIMS could be ideal), and says he thinks NVO is a buy at current levels.
-
27 Feb 26
February portfolio recap: -15.6% for the month but only -0.9% YTD after January's run-up. Attributes the drawdown to a valuation reset in high-conviction AI/software names, volatility in high-beta growth holdings, and resilience from semiconductor/foundational holdings. Made zero trades in February, reaffirms conviction in his 16-company portfolio, framing inactivity as a deliberate choice not to interrupt long-term compounding.
-
27 Feb 26
Asks whether IBRX is preferred over HIMS, questioning a prior comparison.
-
27 Feb 26
Lists his 'unpopular opinions' as head-to-head preferences across sectors: GOOGL over NVDA, FLNC over EOSE, AMPX over ONDS, HIMS over NVO, PL over ASTS, IREN over NBIS, and NU over SOFI.
-
23 Feb 26
Calls this the worst possible chart for $HIMS; likes the business ideas but questions execution given the fast-growing TAM they are positioned in.
-
23 Feb 26
Notes $HIMS is down 1% after missing revenue estimates; Q4 revenue grew 28% YoY but net income fell, gross margin shrank, and free cash flow turned negative due to heavy infrastructure/international investment, with regulatory uncertainty around weight-loss drugs also weighing on sentiment.
-
21 Feb 26
Agrees a HIMS turnaround is coming but is unsure on timing.
-
21 Feb 26
Previews HIMS Q4 earnings ahead of Monday report: low expectations after ~76% stock crash tied to FDA/Novo Nordisk crackdown on compounded weight-loss drugs; notes the $1.15B Eucalyptus acquisition and new offerings (labs, cancer screening) as strategy to change the narrative. Attached earnings sheet shows margins, EPS/revenue beat-miss history and Q4 estimates. Asks followers what they expect.
-
19 Feb 26
Agrees that patient HIMS investors' time to buy has come, given the risk/reward on the acquisition spend discussed by the commenter.
-
19 Feb 26
Bullish on $HIMS after its Eucalyptus, YourBio Health, Zava, and MedisourceRx acquisitions; believes the stock is valued like a dead company and is confident adding at these levels.
-
13 Feb 26
Names HIMS and HOOD as his biggest losers so far, asks the other user about theirs.
-
10 Feb 26
Answering a 'would you rather lose money on X or Y' question, he picks $HIMS, backed by a screenshot of his own portfolio showing the HIMS position down 63.78%.
-
08 Feb 26
Sees HIMS as well positioned for a huge TAM but is critical of management maturity and recent decisions; still holding the position while waiting to see how it plays out.
-
08 Feb 26
Asks how long the parent poster has held their HIMS position; no view of his own expressed.
-
07 Feb 26
Asks the parent poster whether they trust HIMS management, noting management seems good at finding ideas but struggles maturing the business; a question, not a firm stance.
-
06 Feb 26
Asks whether HIMS's price weakness is due to internal focus or external market factors, framing the drop as a possible opportunity if it's the latter.
-
06 Feb 26
Views HIMS's 9%+ drop as an overreaction; says the company has strong platform diversification (Labs, international expansion, cancer testing) but management lacks the seasoned execution maturity to scale the strategy, and bringing in a veteran executive would be a de-risking event.
-
06 Feb 26
Compares the current pullback across a basket of names to the April 2025 correction, noting the current drawdowns are less severe/more concentrated than April for most names.
-
05 Feb 26
Long-term bull case for HIMS: despite the stock being roughly flat over 5 years, underlying fundamentals (revenue +1,044%, subscribers +346%, gross margin 29%->75%, FCF margin -214%->6.06%, ROIC -80%->9.08%) have transformed dramatically, with brand and category expansion (HERS, mental health, ZAVA/Apostrophe acquisitions, MedMatch AI, national labs). Views NVO-related struggles as offset by other high-growth verticals building toward a generational consumer health platform.
-
05 Feb 26
Asked for best GLP-1 exposure, jokingly names HIMS instead of the pharma majors suggested.
-
02 Feb 26
January portfolio update: up 11.56% for the month with no trades made. For the first time in two years PLTR is not his largest holding; PL is now the top position. Full 16-name portfolio with allocation weights disclosed.
-
02 Feb 26
Flags HIMS Q4 earnings date, calling it a big moment as the company badly needs a turnaround.